Rapamycin, metformin blunt exercise gains
- Rapamycin and metformin — two drugs popular in longevity circles and diabetes care — are colliding with a basic assumption: that they stack cleanly with exercise. - In a 13-week rapamycin trial, older adults on weekly sirolimus did not improve more than placebo and may have gained about two fewer chair-stands. - That matters because exercise is the proven intervention here — and these drugs may shave off some of its most reliable payoffs.
Exercise is the simple part of the longevity story. Move more, get stronger, improve insulin control, protect blood vessels, age better. The awkward part is what happens when people try to layer “anti-aging” drugs on top of that. New reporting on rapamycin, plus newer clinical data on metformin, is pushing the same message: these drugs do not necessarily add to exercise — and they may blunt some of the gains instead. (washingtonpost.com) ### Why are these two drugs even in the same conversation? Rapamycin and metformin come from different worlds, but they meet in longevity culture. Rapamycin — usually sirolimus in human studies — targets the mTOR pathway, which helps regulate growth and protein synthesis. Metformin is a diabetes drug that changes how cells handle energy and glucose. Both have (washingtonpost.com)e works through some of the same adaptation machinery, so a drug that quiets those signals can also muffle the body’s training response. (onlinelibrary.wiley.com) ### What changed with rapamycin? The new human result came from RAPA-EX-01, an exploratory randomized, double-blind, placebo-controlled trial in 40 sedentary adults ages 65 to 85. Participants did a 13-week home exercise program and took either weekly sirolimus 6 mg or placebo. The idea was clever — dose the drug once a week, after the last workout, and maybe keep its lon(onlinelibrary.wiley.com)en. The drug did not enhance functional performance, and the paper says it may have attenuated training-induced gains instead. (onlinelibrary.wiley.com) ### What did the rapamycin group actually lose? Not everything got worse, but the expected edge never showed up. Both groups improved on the 30-second chair-stand test, yet the sirolimus group ended the study about two repetitions behind placebo on average in reporting tied to the trial. The regimen also produced more minor adverse events, and the paper notes a possible c(onlinelibrary.wiley.com)ike extra downside for people who were already doing the thing with the strongest evidence base, which is exercise. (nad.com) ### And metformin? Metformin’s warning light has been blinking longer. A 2025 double-blind trial in adults at risk for metabolic syndrome tested whether metformin changes the vascular and metabolic response to exercise training. Exercise without metformin improved aerobic fitness, blood vessel function, and blood sugar control more than exercise with the(nad.com)exercise training. Related work also found that the drug attenuated metabolic insulin sensitivity and carbohydrate oxidation after high-intensity training. (academic.oup.com) ### Why would a drug blunt exercise at all? Because exercise is controlled stress. You damage muscle a bit, burn fuel hard, trigger signaling, then rebuild stronger. Rapamycin blocks mTOR, which is one of the main “build and adapt” signals. Metformin changes mitochondrial and energy signaling in ways that can reduce some exercise-triggered adaptations. Basically, if train(academic.oup.com)es on the rehearsal. That can be useful in one context and unhelpful in another. (onlinelibrary.wiley.com) ### Does this mean nobody should take them? No — but it does mean the tradeoff is more concrete now. Metformin still has an established role in glucose management. Sirolimus still has real medical uses, and rapamycin’s longevity promise in animals is why people keep chasing it. But for a healthy person taking either drug mainly to age better, the bar is much higher if the drug trims the benefits of training. Exercise is not the add-on here. The drug is. (pharmacytimes.com) ### So what’s the bottom line? If your goal is better aging, better fitness, and better metabolic health, exercise remains the anchor. Rapamycin has now shown disappointing human exercise data, and metformin keeps looking less like a free bonus and more like a possible compromise. The big lesson is simple — stacking interventions is not automatically additive, especially when they push on the same biology. (washingtonpost.com)
